Endothelial cells (EC) play a central role in inflammatory immune
I
nducible costimulator-ligand (ICOS-L) is a member of the B7 family of costimulatory ligands (1, 2) sharing 19-20% sequence identity with CD80 and CD86. Two splice variants of human ICOS-L have been described and designated hGL50 (3) and B7-H2͞B7RP-1͞hLICOS (4) (5) (6) . Both molecules have an identical extracellular domain but differ at the carboxyl-terminal end of their cytoplasmic regions. In humans, cell surface expression of ICOS-L has been described on B cells, dendritic cells, monocytes͞macrophages, and T cells (refs. 1 and 2; unpublished data). In addition, mRNA expression of ICOS-L has been detected in a variety of lymphoid and nonlymphoid organs, with hGL50 showing a more lymphoid-restricted expression pattern (spleen, lymph node), whereas B7-H2͞B7RP-1͞hLICOS mRNA was expressed in all organs examined (e.g., spleen, kidney, heart, and brain; ref. 7) .
ICOS-L, unlike CD80 and CD86, does not interact with CD28 or CTLA-4 (CD152; refs. 8 and 9). Instead, ICOS-L binds to ICOS, a T cell-specific costimulatory molecule homologous to CD28 and CTLA-4 (8) (9) (10) . The strong impact of ICOS͞ICOS-L interaction on T cell-mediated immune responses in vivo became evident by the disruption of the ICOS gene in mice. ICOSdeficient mice are characterized by impaired germinal center formation, have a profound defect in isotype class switching in T cell-dependent B cell responses, and are defective in IL-4 and IL-13 production (11) (12) (13) . In addition, blockade of ICOS͞ ICOS-L interaction in animal models of experimental allergic encephalomyelitis (14) and of cardiac allograft rejection (15) revealed a critical role of ICOS and its ligand in inflammatory immune reactions.
Endothelial cells (EC) play an important role in the recruitment of T cells and their activation at sites of inflammation (16) (17) (18) . Human EC either constitutively express or up-regulate MHC class II molecules after exposure to IFN-␥ (16) (17) (18) . It has therefore been suggested that human EC might play a role in secondary immune responses by presenting antigen to circulating CD4 ϩ memory T cells (18) . Many in vitro studies have supported this notion by demonstrating that EC can stimulate CD4 ϩ T cells in an antigen-specific manner (19, 20) . However, in contrast to professional antigen-presenting cells like dendritic cells, human EC do not express the costimulatory ligands CD80 and CD86, which may explain the inability of EC to activate naive T cells (16, 18) . Previous studies have demonstrated that activation of T cells by EC involves the interaction of LFA-3 (CD58) and OX40L (CD134L) with their corresponding receptors on T cells (21, 22) . However, these molecules can account for only some of the accessory cell functions of EC, indicating the presence of an as-yet-unidentified costimulatory molecule.
In the present report, we demonstrate that human EC express ICOS-L, a member of the B-7 family of costimulatory ligands, in vitro and in vivo. Moreover, we describe its biochemical characteristics and its regulation by inflammatory stimuli, and we provide data demonstrating that ICOS-L plays an important functional role in the activation of T cells by EC.
Materials and Methods

Generation of L Cell Transfectants Expressing ICOS-L.
A human ICOS-L cDNA fragment was cloned into the expression vector BCMGS neo (23) . The recombinant plasmid was transfected by electroporation into mouse fibroblastic Ltk Ϫ cells (L cells). Transfectants expressing ICOS-L were identified by flow cytometry by using a muICOS-Ig fusion protein (24) .
Cell Isolation. Human umbilical vein endothelial cells (HUVEC) were isolated from umbilical cords with 2.4 units͞ml Dispase II (Roche Molecular Biochemicals) and cultured in endothelial growth medium with EC growth supplement (Promo Cell, Heidelberg) on gelatin-coated tissue culture vessels. Microvascular endothelial cells (MVEC) were obtained from explanted human hearts and cultured as described (25) . In addition to HIL-131, a soluble human ICOS-rabbit-Ig fusion protein coupled to PE was used for ICOS-L staining. mAb 2A11 (IgG1, own hybridoma) and CD3␦-rabbit-Ig coupled to the appropriate chromophore, were used as isotype controls. The specificity of binding of HIL-131 and ICOS-Ig was further controlled by blocking experiments with a 50-to 100-fold excess of an unconjugated reagent (cold blocking control).
Reverse Transcription-PCR of ICOS-L Splice Variants. RNA obtained from untreated or tumor necrosis factor ␣ (TNF-␣)-stimulated (48 h) HUVEC was reverse-transcribed by using the Superscript II enzyme from Life Technologies, Rockville, MD. The singlestranded cDNA was used to amplify the ICOS-L splice variants hGL50 and B7-H2͞B7RP-1͞hLICOS by PCR with Pfu DNA polymerase from Stratagene. The forward primer VL141 and the downstream primers VL274 (specific for B7-H2͞B7RP-1͞ hLICOS) and VL162B (specific for hGL50) used for amplification have been described (7) . Primers VL274 and VL162B were slightly modified by the addition of a NotI restriction site to their 3Ј end. Cycle conditions were 94°C for 40 sec, 62°C for 1 min, and 75°C for 2 min for 38 cycles. The PCR products were separated on 2% agarose gels. Immunohistology. Cryostat sections (8 m) of umbilical cords or human tonsils were prepared, fixed in acetone, and immunostained with the mAb HIL-131 or BV6 (anti-CD144), followed by biotinylated goat anti-mouse antibody (Dianova, Hamburg, Germany) and streptavidin-horseradish peroxidase (Dianova); 3-amino-9-ethylcarbazole was used as substrate (Sigma). Nuclei were counterstained with hematoxylin. 
Results mAb HIL-131 Binds to ICOS-L and Inhibits the Interaction with ICOS.
To analyze ICOS-L expression and function we generated a panel of mAbs directed to human ICOS-L. The specificity of these mAbs was confirmed by staining of ICOS-L transfectants. The reactivity pattern of one of the mAbs obtained (clone HIL-131) is shown in Fig. 1A . We further investigated the capacity of our mAbs to prevent binding of ICOS to its ligand. We found that mAb HIL-131, at low concentrations, fully blocked the binding of a human ICOS-Ig fusion protein to ICOS-L-transfected L cells (Fig. 1B) . To assess the blocking efficiency of HIL-131, the blockade obtained with an excess of unconjugated ICOS-Ig fusion protein is shown for comparison (Fig. 1B) .
ICOS-L Is Constitutively Expressed by EC and Strongly Up-Regulated by
Inflammatory Stimuli. To explore the expression of ICOS-L on EC, we stained isolated HUVEC and MVEC with the ICOS-L-specific mAb HIL-131. As shown in Fig. 2 A and (Fig. 2 A and B) , LPS (Fig. 2 A) or stimulation of EC by CD40 (Fig. 2B) led to an increase in ICOS-L expression. The most striking effect was observed with the inflammatory cytokines IL-1␤ and TNF-␣, which both very effectively enhanced ICOS-L expression on HUVEC and MVEC ( Fig. 2 A and B) . In clear contrast to the expression of ICOS-L by EC, expression of CD80 or CD86 could not be detected on HUVEC or MVEC (data not shown; refs. 16 and 18).
Time Course of ICOS-L Expression by TNF-␣-Treated HUVEC.
HUVEC were stimulated with TNF-␣, and ICOS-L expression was investigated after various times by flow cytometry. ICOS-L upregulation was already detectable 5 h after stimulation, reached a maximum at 24-48 h, and gradually declined thereafter (Fig.  3) . The continuos presence of TNF-␣ seemed to be necessary for high-level ICOS-L expression, because removal of TNF-␣ after 24 h by washing the cells and culturing them in fresh medium led to a rapid decrease of ICOS-L expression (data not shown).
Both ICOS-L Splice Variants Are Expressed by EC.
To analyze the expression of ICOS-L splice variants in EC, we performed reverse transcription-PCR with primer sets specific for hGL50 and B7-H2͞B7RP-1͞hLICOS by using RNA isolated from unstimulated and TNF-␣-stimulated HUVEC. As shown in Fig. 4 , transcripts for B7-H2͞B7RP-1͞hLICOS could be detected in unstimulated and stimulated HUVEC, whereas a signal for hGL50 was observed only with RNA obtained from TNF-␣-treated HUVEC. These results indicate that both ICOS-L splice variants are made by EC.
Biochemical Characterization of ICOS-L Expressed by EC.
To determine the biochemical features of ICOS-L, we performed immunoprecipitation studies on TNF-␣-stimulated HUVEC by using mAb HIL-131. We detected one single band at 63-72 kDa under nonreducing and reducing conditions (Fig. 5) , indicating that ICOS-L is expressed as a monomer on the surface of EC. Treatment of the immunoprecipitate with N-glycosidase F reduced the apparent M r of ICOS-L to approximately 35-38 kDa (Fig. 5) , indicating that ICOS-L is highly glycosylated. The M r of the deglycosylated protein slightly differs from the predicted M r of the mature protein backbone of ICOS-L (31.4 kDa for B7-H2͞B7RP-1͞hLICOS or 32.3 kDa for hGL50 without the putative signal peptide), suggesting other as-yet-undefined posttranslational modifications.
ICOS-L Expression by EC in Vivo.
To support our in vitro findings, we examined the expression of ICOS-L in vivo by immunostaining frozen tissue sections from umbilical cords and human tonsils with mAb HIL-131. The venular (Fig. 6A ) and the arteriolar (data not shown) EC layers of the umbilical cord stained strongly for ICOS-L. ICOS-L expression on EC was also observed in other tissues, as exemplified by the staining of small blood vessel EC in human tonsils (Fig. 6B ). These data demonstrate that ICOS-L is expressed on EC in vivo. For comparison, also shown is the staining pattern of VE-Cadherin (CD144), an EC-specific marker (ref. 36 ; Fig. 6 C and D) . (Fig. 7) . On activation of these cells with HUVEC, a slight increase in ICOS expression was observed with a maximum at 72 h. When HUVEC were cocultured with CD4 ϩ CD45RO ϩ T cells, ICOS was more rapidly and more strongly induced (mean fluorescence intensity, 44 vs. 190 at 72 h; Fig. 7 ). Up-regulation of ICOS was not observed on T cells stimulated with SAg alone at any time point (data not shown). For comparison also shown is the expression of CD25 (Fig. 7) . Fig. 4 . Reverse transcription-PCR analysis of ICOS-L splice variants. cDNA generated from unstimulated or TNF-␣-stimulated HUVEC was amplified by using primer pairs specific for hGL50 or B7-H2͞B7RP-1͞hLICOS. The resulting PCR fragments were separated by agarose gel electrophoresis. Twenty microliters of the hGL50 and 10 l of the B7-H2͞B7RP-1͞hLICOS PCR products were loaded. Unst., unstimulated.
ICOS-L mAb HIL-131 Inhibits EC-Mediated Cytokine Production But Not the Expression of T Cell Adhesion Molecules. We next investigated the functional consequences of the interaction of ICOS-L on EC
Fig. 5.
Immunoprecipitation of ICOS-L. TNF-␣-stimulated HUVEC were surface-iodinated and ICOS-L protein was immunoprecipitated with anti-ICOS-L mAb HIL-131. Immunoprecipitates were separated by SDS͞PAGE under nonreducing or reducing conditions. In some experiments, the immunoprecipitate was treated by N-glycosidase F before analysis under reducing conditions. (Fig. 8) . A similar result was obtained with a different mAb directed against ICOS-L (data not shown). For comparison, cocultures were also performed in the presence of TS2͞9 (anti-LFA-3), a mAb known to inhibit T cell activation by EC (21) . As a result, TS2͞9 blocked the secretion of IL-2 and IFN-␥ to a similar extent as HIL-131, and also inhibited the secretion of IL-4 and IL-10, albeit with lower efficiency. In contrast to mAb HIL-131, mAb TS2͞9 did not inhibit IL-13 production (Fig.  8) . By combining the blocking effects achieved with HIL-131 and TS2͞9, the inhibition reached levels obtained with the anti-MHC class II mAb L243 (Fig. 8) . No cytokines could be detected, when T cells were cultured with SAg in the absence of EC.
In separate EC͞T cell coculture experiments we also analyzed the influence of ICOS͞ICOS-L interaction on the expression of various T cell adhesion molecules (CD62L, CD162, CLA, CD49d, CD11a, LFA-3, CXCR3, CXCR4, CCR7, CD43, and CD44) by CD45RO ϩ T cells. As a result, we found that the expression levels of none of these markers could be influenced by the blocking mAb HIL-131 (data not shown). (Fig. 9) . In contrast, when cocultures were performed with CD4 ϩ CD45RO ϩ T cells, up to 50% of the T cells divided. Whereas treatment of the cocultures with the anti-MHC class II mAb L243 reduced T cell proliferation to background levels, only a slight inhibition was observed by treatment of the cocultures with HIL-131, indicating that ICOS͞ ICOS-L-interaction has only a minor influence on EC-induced T cell proliferation (Fig. 9) .
Influence of ICOS͞ICOS-L Interaction on EC-
Discussion
The expression of costimulatory ligands of the B7 family enables antigen-presenting cells to initiate and maintain effective T cell responses (1, 2) . Although human EC do not express CD80 or CD86, they nevertheless have the capacity to potently activate T cell effector functions in vitro.
We now demonstrate that human EC are endowed with a ''professional'' costimulatory ligand of the B7 family, ICOS-L. We further show that ICOS-L, a glycosylated monomer of 63-72 kDa, is expressed on the cell surface of EC in vitro and in vivo, and is up-regulated by various inflammatory stimuli including TNF-␣, IL-1␤, and LPS, or by triggering by CD40. Most importantly, ICOS-L on EC is functional, as demonstrated by its capacity to costimulate cytokine secretion in cocultures of T cells with EC. Together with the observation that EC express MHC class II molecules, the finding of ICOS-L expression on EC in vivo lends strong support to the notion that EC function as accessory cells for CD4 (38) . On the basis of previous data, we and others suggested a model in which CD28 costimulates primary T cell functions, whereas ICOS plays a more prominent role in the costimulation of effector or memory T cell responses (10, 39) . Our functional data presented here are in agreement with such a concept. In contrast to SAg-driven cocultures performed with EC and memory T cells, cocultures with naive CD4 ϩ CD45RA ϩ T cells did not result in any measurable cytokine secretion (ref. 37 and this report), a finding that may be attributed to the lack of CD80͞CD86 expression on EC. Thus, our data clearly demonstrate that ICOS-L expressed on EC delivers costimulatory signals to memory cells, but cannot replace CD80͞CD86 in priming naive T cells.
As revealed by mRNA expression studies, ICOS-L is expressed in lymphoid and nonlymphoid organs (3, 7) . B cells, T cells, and dendritic cells, which all have been shown to express ICOS-L on their cell surface, may account for ICOS-L expression in lymphoid organs; the cell type responsible for high-level expression of ICOS-L in nonlymphoid tissues, e.g., kidney, heart, or brain, has not been identified to date. Our data indicate that EC represent a major source of ICOS-L in these organs. Expression of ICOS-L on EC may also explain findings from a previous study in mice, in which a rapid up-regulation of ICOS-L was observed in various nonlymphoid tissues after in vivo injection of LPS (34) . Moreover, both ICOS-L splice variants are expressed by EC stimulated with TNF-␣, indicating that under certain inflammatory conditions ICOS-L splice variant hGL50 might also be expressed on nonlymphoid tissues, in addition to B7-H2͞B7RP-1͞hLICOS. With regard to tissue distribution, ICOS-L differs strikingly from CD80 and CD86, whose expression is largely confined to professional antigen-presenting cells within lymphoid tissue (2, 34, 40) , suggesting a unique function for ICOS-L during immune reactions in nonlymphoid organs.
EC and CD4 ϩ T cells interact and are activated during immune reactions and, if not properly controlled, are thought to contribute to the immunopathogenesis of inflammatory diseases. In this context, our finding that the basal expression of ICOS-L on EC could be strongly enhanced by inflammatory mediators like TNF-␣, IL-1␤, or LPS, is of particular interest. On the basis of these findings, it can be assumed that in the course of an infection, cells of the innate immune system will locally produce the inflammatory cytokines IFN-␥, TNF-␣, and IL-1. Stimulation by IFN-␥ will enable EC to present antigen by up-regulating MHC-class II molecules, whereas stimulation by TNF-␣͞IL-1 will endow EC with the ICOS-L. ICOS-expressing antigen-specific T cells, generated in secondary lymphoid organs, once attracted to the site of inflammation, will reencounter their cognate antigen presented by EC. Costimulation of these effector T cells by ICOS is likely to significantly contribute to their reactivation and subsequent extravasation to the underlying tissue. A similar mechanism may be operative in noninfectious inf lammator y conditions. For example, ICOS͞ICOS-Linteraction was critical in experimental allergic encephalomyelitis and allograft rejection (14, 15) , murine disease models in which CD4 ϩ T cells and EC are known to participate in the disease process.
Collectively, our data suggest that ICOS-L expressed on EC, in the absence of CD80 and CD86, plays a major role for the reactivation of effector͞memory T cells on the endothelium controlling the entry of immune cells into inflamed tissue.
